Metabolic reprogramming of skeletal muscle by resident macrophages points to CSF1R inhibitors as muscular dystrophy therapeutics

Sci Transl Med. 2022 Jun 29;14(651):eabg7504. doi: 10.1126/scitranslmed.abg7504. Epub 2022 Jun 29.

Abstract

The role of tissue-resident macrophages during tissue regeneration or fibrosis is not well understood, mainly due to the lack of a specific marker for their identification. Here, we identified three populations of skeletal muscle-resident myelomonocytic cells: a population of macrophages positive for lymphatic vessel endothelial receptor 1 (LYVE1) and T cell membrane protein 4 (TIM4 or TIMD4), a population of LYVE1-TIM4- macrophages, and a population of cells likely representing dendritic cells that were positive for CD11C and major histocompatibility complex class II (MHCII). Using a combination of parabiosis and lineage-tracing experiments, we found that, at steady state, TIM4- macrophages were replenished from the blood, whereas TIM4+ macrophages locally self-renewed [self-renewing resident macrophages (SRRMs)]. We further showed that Timd4 could be reliably used to distinguish SRRMs from damage-induced infiltrating macrophages. Using a colony-stimulating factor 1 receptor (CSF1R) inhibition/withdrawal approach to specifically deplete SRRMs, we found that SRRMs provided a nonredundant function in clearing damage-induced apoptotic cells early after extensive acute injury. In contrast, in chronic mild injury as seen in a mouse model of Duchenne muscular dystrophy, depletion of both TIM4-- and TIM4+-resident macrophage populations through long-term CSF1R inhibition changed muscle fiber composition from damage-sensitive glycolytic fibers toward damage-resistant glycolytic-oxidative fibers, thereby protecting muscle against contraction-induced injury both ex vivo and in vivo. This work reveals a previously unidentified role for resident macrophages in modulating tissue metabolism and may have therapeutic potential given the ongoing clinical testing of CSF1R inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Macrophages* / metabolism
  • Macrophages* / pathology
  • Membrane Proteins / metabolism
  • Mice
  • Monocytes / metabolism
  • Monocytes / pathology
  • Muscle, Skeletal* / metabolism
  • Muscle, Skeletal* / pathology
  • Muscular Dystrophies* / drug therapy
  • Muscular Dystrophies* / metabolism
  • Muscular Dystrophies* / pathology
  • Receptor Protein-Tyrosine Kinases / metabolism
  • Receptors, Granulocyte-Macrophage Colony-Stimulating Factor* / antagonists & inhibitors
  • Receptors, Granulocyte-Macrophage Colony-Stimulating Factor* / metabolism
  • Vesicular Transport Proteins / metabolism

Substances

  • Csf1r protein, mouse
  • LYVE1 protein, mouse
  • Membrane Proteins
  • Receptors, Granulocyte-Macrophage Colony-Stimulating Factor
  • TIM-4 protein, mouse
  • Vesicular Transport Proteins
  • Receptor Protein-Tyrosine Kinases

Grants and funding